Literature DB >> 9169039

Homozygous deletion of the neurofibromatosis-1 gene in the tumor of a patient with neuroblastoma.

T Martinsson1, R M Sjöberg, F Hedborg, P Kogner.   

Abstract

The neurofibromatosis type 1 (von Recklinghausen, NF1) gene has been proposed as a suppressor gene in tumors associated with neurofibromatosis. Recent publications have indicated that the NF1 gene can be rearranged in neuroblastoma cell lines. We analyzed DNA from a neuroblastoma patient with NF1 inherited as a familial trait on the paternal side. Using PCR and Southern techniques we showed that the patient had a constitutional deletion of several exons of the paternally derived NF1 gene and that the maternal copy of the gene had been deleted in the tumor of the patient. This is the first instance of a homozygous deletion reported in a primary neuroblastoma tumor. This suggests that NF1 inactivation in involved in the development or progression of some neuroblastomas in agreement with the hypothesized two hit model of inactivation for a tumor suppressor. These results are concordant with other groups that have detected unbalanced translocations t(1;17) in neuroblastoma tumors, with a breakpoint in chromosome 17 that may coincide with the location of the NF1 gene.

Entities:  

Mesh:

Year:  1997        PMID: 9169039     DOI: 10.1016/s0165-4608(96)00259-2

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

1.  NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.

Authors:  Michael Hölzel; Sidong Huang; Jan Koster; Ingrid Ora; Arjan Lakeman; Huib Caron; Wouter Nijkamp; Jing Xie; Tom Callens; Shahab Asgharzadeh; Robert C Seeger; Ludwine Messiaen; Rogier Versteeg; René Bernards
Journal:  Cell       Date:  2010-07-23       Impact factor: 41.582

2.  Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma.

Authors:  Helena Carén; Anna Djos; Maria Nethander; Rose-Marie Sjöberg; Per Kogner; Camilla Enström; Staffan Nilsson; Tommy Martinsson
Journal:  BMC Cancer       Date:  2011-02-11       Impact factor: 4.430

Review 3.  Retinoblastoma and Neuroblastoma Predisposition and Surveillance.

Authors:  Junne Kamihara; Franck Bourdeaut; William D Foulkes; Jan J Molenaar; Yaël P Mossé; Akira Nakagawara; Andreu Parareda; Sarah R Scollon; Kami Wolfe Schneider; Alison H Skalet; Lisa J States; Michael F Walsh; Lisa R Diller; Garrett M Brodeur
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

4.  Mutations in PIK3CA are infrequent in neuroblastoma.

Authors:  Vincent Dam; Brian T Morgan; Pavel Mazanek; Michael D Hogarty
Journal:  BMC Cancer       Date:  2006-07-05       Impact factor: 4.430

Review 5.  The NF1 gene revisited - from bench to bedside.

Authors:  Yoon-Sim Yap; John R McPherson; Choon-Kiat Ong; Steven G Rozen; Bin-Tean Teh; Ann S G Lee; David F Callen
Journal:  Oncotarget       Date:  2014-08-15

6.  Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene.

Authors:  K Ejeskär; H Aburatani; J Abrahamsson; P Kogner; T Martinsson
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

7.  High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.

Authors:  Helena Carén; Jennie Erichsen; Linda Olsson; Charlotta Enerbäck; Rose-Marie Sjöberg; Jonas Abrahamsson; Per Kogner; Tommy Martinsson
Journal:  BMC Genomics       Date:  2008-07-29       Impact factor: 3.969

Review 8.  Genetic Predisposition to Neuroblastoma.

Authors:  Erin K Barr; Mark A Applebaum
Journal:  Children (Basel)       Date:  2018-08-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.